Table 4.
Top 20 co-cited references related to CAR-based immunotherapy.
| Rank | Reference | Citations | Author | Year | Type | Journal | IF | JCR |
|---|---|---|---|---|---|---|---|---|
| 1 | Chimeric antigen receptor t cells for sustained remissions in leukemia | 958 | Maude Shannon L | 2014 | Article(CT) | The New England Journal of Medicine | 91.245 | Q1 |
| 2 | T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial | 813 | Lee Daniel W | 2015 | Article(CT) | LANCET | 79.321 | Q1 |
| 3 | Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia | 799 | Maude Shannon L | 2018 | Article(CT) | The New England Journal of Medicine | 91.245 | Q1 |
| 4 | Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma | 766 | Neelapu Sattva S | 2017 | Article(CT) | The New England Journal of Medicine | 91.245 | Q1 |
| 5 | Chimeric Antigen Receptor–Modified T Cellsfor Acute Lymphoid Leukemia | 662 | Grupp Stephan A | 2013 | Article(CT) | The New England Journal of Medicine | 91.245 | Q1 |
| 6 | Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia | 637 | Davila Marco L | 2014 | Article(CT) | Science Translational Medicine | 17.956 | Q1 |
| 7 | CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients | 579 | Turtle Cameron J | 2016 | Article(CT) | Journal of Clinical Investigation | 14.808 | Q1 |
| 8 | Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated with Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor | 559 | Kochenderfer James N | 2015 | Article(CT) | Journal of Clinical Oncology | 44.544 | Q1 |
| 9 | CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia | 539 | Brentjens Renier J | 2013 | Article(CT) | Science Translational Medicine | 17.956 | Q1 |
| 10 | Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia | 497 | Porter David L | 2015 | Article(CT) | Science Translational Medicine | 17.956 | Q1 |
| 11 | Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia | 475 | Porter David L | 2011 | Article(CR) | The New England Journal of Medicine | 91.245 | Q1 |
| 12 | Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia | 469 | Park Jae H | 2018 | Article(CT) | The New England Journal of Medicine | 91.245 | Q1 |
| 13 | Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy | 398 | Brown Christine E | 2016 | Article(CR) | The New England Journal of Medicine | 91.245 | Q1 |
| 14 | Chimeric antigen receptor T−cell therapy — assessment and management of toxicities | 398 | Neelapu Sattva S | 2017 | Review | Nature Reviews Clinical Oncology | 66.675 | Q1 |
| 15 | Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma | 393 | Schuster Stephen J | 2019 | Article(CT) | The New England Journal of Medicine | 91.245 | Q1 |
| 16 | B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor–transduced T cells | 390 | Kochenderfer James N | 2012 | Article(CT) | Blood | 22.113 | Q1 |
| 17 | T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia | 387 | Kalos Michael | 2011 | Article(CT) | Science Translational Medicine | 17.956 | Q1 |
| 18 | Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas | 371 | Schuster Stephen J | 2017 | Article(CT) | The New England Journal of Medicine | 91.245 | Q1 |
| 19 | 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors | 362 | Long Adrienne H | 2015 | Article | Nature Medicine | 53.440 | Q1 |
| 20 | A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma | 344 | O’Rourke Donald M | 2017 | Article(CT) | Science Translational Medicine | 17.956 | Q1 |
CT, clinical trial; CR, case report; IF, impact factors; JCR, journal citation reports.